Active ingredient: Acetylcystiene 200mg/5gm

–  Mucolytic
– According to management protocol for COVID-19.
– Acenewrax used in mild case (COVID-19).
– Acenewrax used in home isolation (Symptomatic treatment)
– Acenewrax used 3 times /day in isolation period.

Mechanism of action:

-Acetylcysteine exerts its mucolytic action through its free sulfhydryl group, which reduces the disulfide bonds in the mucus matrix and lowers mucus viscosity.

– Indications:
  • Mucolytic adjuvant in the therapy of respiratory disorders associated with thick, viscous, mucus hypersecretion.
  • Chronic bronchopulmonary disease , chronic emphysema , emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary
  • amyloidosis of the lung.
  • Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis).
  • Pulmonary complications of cystic fibrosis.
  • Tracheostomy care.
  • Pulmonary complications associated with surgery.
  • Use during anesthesia.
  • Post-traumatic chest conditions.

Learn more about the Acenewrax Trial….. Click here

Description

This guidance document is intended for clinicians caring for COVID-19 patients during all phases of their disease (i.e. screening to discharge).

Powered by: The Egyptian Ministry of Health and Population

Acenewrax BANNER

Where can you find this Product?